retatrutide dosing clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity retatrutide dosing schedule clinical trial

The findings of these studies combined clearly suggests that early management with GLP-1 receptor agonists may successfully prevent the development from simple steatosis to more serious liver disease

In November 2023, tirzepatide was also approved for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity

Youre not impossible to treat

Clinicians should interpret preliminary findings with appropriate caution and await results from adequately powered randomized controlled trials before drawing firm conclusions about neuroprotective benefits

++ | STRUCTURAL REPAIR PROTOCOLS | ++ | 1